0000000000324791

AUTHOR

Katy Jeannot

showing 7 related works from this author

The Efflux Pump MexXY/OprM Contributes to the Tolerance and Acquired Resistance of Pseudomonas aeruginosa to Colistin

2020

The intrinsic resistance of Pseudomonas aeruginosa to polymyxins in part relies on the addition of 4-amino-4-deoxy-l-arabinose (Ara4N) molecules to the lipid A of lipopolysaccharide (LPS), through induction of operon arnBCADTEF-ugd (arn) expression. As demonstrated previously, at least three two-component regulatory systems (PmrAB, ParRS, and CprRS) are able to upregulate this operon when bacteria are exposed to colistin. In the present study, gene deletion experiments with the bioluminescent strain PAO1::lux showed that ParRS is a key element in the tolerance of P. aeruginosa to this last-resort antibiotic (i.e., resistance to early drug killing). Other loci of the ParR regulon, such as th…

medicine.drug_classOperonPolymyxinMutantMicrobial Sensitivity Testsmedicine.disease_causeMicrobiologyLipid A03 medical and health sciencesBacterial ProteinsMechanisms of ResistanceDrug Resistance BacterialmedicinePharmacology (medical)ComputingMilieux_MISCELLANEOUS030304 developmental biologyPharmacology0303 health sciencesColistin030306 microbiologyPseudomonas aeruginosaChemistryMembrane Transport ProteinsGene Expression Regulation BacterialAnti-Bacterial AgentsInfectious DiseasesRegulonPseudomonas aeruginosa[SDE]Environmental SciencesColistinlipids (amino acids peptides and proteins)EffluxGene DeletionBacterial Outer Membrane Proteinsmedicine.drugAntimicrobial Agents and Chemotherapy
researchProduct

The unusual structure of Ruminococcin C1 antimicrobial peptide confers clinical properties.

2020

The emergence of superbugs developing resistance to antibiotics and the resurgence of microbial infections have led scientists to start an antimicrobial arms race. In this context, we have previously identified an active RiPP, the Ruminococcin C1, naturally produced by Ruminococcus gnavus E1, a symbiont of the healthy human intestinal microbiota. This RiPP, subclassified as a sactipeptide, requires the host digestive system to become active against pathogenic Clostridia and multidrug-resistant strains. Here, we report its unique compact structure on the basis of four intramolecular thioether bridges introduced post-translationally by a specific radical-SAM sactisynthase. This structure con…

0301 basic medicinemedicine.drug_class[CHIM.THER] Chemical Sciences/Medicinal ChemistryAntibioticsgut microbiomeContext (language use)Peptide[CHIM.THER]Chemical Sciences/Medicinal Chemistry010402 general chemistry01 natural sciencesMicrobiologyClostridia03 medical and health sciencesRuminococcus gnavusantibioticmedicineRiPPHumansIntestinal Mucosa[SDV.MP] Life Sciences [q-bio]/Microbiology and Parasitologychemistry.chemical_classificationRadical SAM enzymeClostridialesMultidisciplinarybiologyRiPPs Ruminococcin C sactipeptide gut microbiome antibiotic[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyBacterial InfectionsBiological Sciencesbiology.organism_classificationAntimicrobialIntestinal epithelium[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology0104 chemical sciences3. Good healthsactipeptideAnti-Bacterial AgentsRuminococcus gnavusRiPPs030104 developmental biology[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologychemistryRuminococcin CPeptidesBacteriaProceedings of the National Academy of Sciences of the United States of America
researchProduct

Coordinate overexpression of two RND efflux systems, ParXY and TtgABC , is responsible for multidrug resistance in Pseudomonas putida

2020

Resistance Nodulation cell Division (RND) efflux pumps are known to contribute to the tolerance of Pseudomonas putida to aromatic hydrocarbons, but their role in antibiotic resistance has not been fully elucidated. In this study, two types of single-step multidrug-resistant (MDR) mutants were selected in vitro from reference strain KT2440. Mutants of the first type were more resistant to fluoroquinolones and β-lactams except imipenem, and overproduced the efflux system TtgABC as a result of mutations occurring in regulator TtgR. In addition to TtgABC, mutants of the second type such as HPG-5 were found to upregulate a novel RND pump, dubbed ParXY/TtgC, which accommodates cefepim, fluoroquin…

MutantGlyoxylate cycleMicrobial Sensitivity Testsmedicine.disease_causeMicrobiologyMicrobiology03 medical and health sciencesAntibiotic resistanceBacterial ProteinsDrug Resistance Multiple BacterialmedicineGeneEcology Evolution Behavior and SystematicsComputingMilieux_MISCELLANEOUS030304 developmental biology0303 health sciencesMutationbiology030306 microbiologyPseudomonas putidaMembrane Transport ProteinsBiological TransportGene Expression Regulation Bacterialbiology.organism_classificationPseudomonas putidaAnti-Bacterial AgentsMultiple drug resistance[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyMutationEffluxCell Division
researchProduct

Performance of disc diffusion, MIC gradient tests and Vitek 2 for ceftolozane/tazobactam and ceftazidime/avibactam susceptibility testing of Pseudomo…

2021

AbstractObjectivesTo assess performance of disc diffusion, gradient tests and Vitek 2 system to determine the susceptibility of clinical Pseudomonas aeruginosa strains to ceftolozane/tazobactam (C/T) and ceftazidime/avibactam (CZA).MethodsTwo-hundred non-duplicate P. aeruginosa strains isolated by 47 French medical laboratories were selected to cover a wide range of C/T and CZA MICs. Performance of C/T disc (30/10 μg, Bio-Rad), CZA discs (10/4 μg) (Thermo Fisher and Bio-Rad), C/T and CZA gradient tests (Etest, BioMérieux; MIC Test Strip, Liofilchem), and AST-XN12 card of Vitek 2 system (BioMérieux) were compared with a broth microdilution (BMD) method (Thermo Fisher). MIC and disc results w…

0301 basic medicineMicrobiology (medical)TazobactamAvibactam030106 microbiologyCeftazidimeMicrobial Sensitivity Testsmedicine.disease_causeTazobactamCeftazidime03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHumansPharmacology (medical)Pseudomonas Infections030212 general & internal medicineEtestPharmacologyChromatographyPseudomonas aeruginosaChemistryBroth microdilutionCeftazidime/avibactamAnti-Bacterial AgentsCephalosporinsDrug CombinationsInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyPseudomonas aeruginosaCeftolozaneAzabicyclo Compoundsmedicine.drug
researchProduct

Acquisition of Class C β-Lactamase PAC-1 by Sequence Type 644 Strains of Pseudomonas aeruginosa

2019

Four sequence type 664 (ST664) (serotype O:5) strains of Pseudomonas aeruginosa that were highly resistant to antibiotics, including ceftolozane-tazobactam and ceftazidime-avibactam, but were susceptible to colistin were found to harbor the gene encoding the rare class C β-lactamase PAC-1 on a chromosomally located Tn 1721 -like transposon. The bla PAC-1 gene was associated with the 16S rRNA methylase determinant rmtF2 , which confers pan-aminoglycoside resistance.

PharmacologyTransposable elementSerotype0303 health sciencesLineage (genetic)030306 microbiologymedicine.drug_classPseudomonas aeruginosaAntibioticseducationBiologymedicine.disease_cause16S ribosomal RNA3. Good healthMicrobiology03 medical and health sciencesInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyColistinmedicinePharmacology (medical)Gene030304 developmental biologymedicine.drug
researchProduct

Production of Norspermidine Contributes to Aminoglycoside Resistance in pmrAB Mutants of Pseudomonas aeruginosa

2019

Emergence of resistance to polymyxins in Pseudomonas aeruginosa is mainly due to mutations in two-components systems, that promote addition of 4-amino-4-deoxy-L-arabinose to the lipopolysaccharide (LPS) through upregulation of operon arnBCADTEF-ugd (arn) expression. Here, we demonstrate that mutations occurring in different domains of histidine kinase PmrB or in response regulator PmrA result in coresistance to aminoglycosides and colistin. All seventeen clinical strains tested exhibiting such a cross-resistance phenotype were found to be pmrAB mutants. As shown by gene deletion experiments, the decreased susceptibility of the mutants to aminoglycosides was independent from operon arn but r…

Spectrometry Mass Electrospray IonizationOperonSpermidineMutantMicrobial Sensitivity TestsMicrobiology03 medical and health scienceschemistry.chemical_compoundBacterial ProteinsMechanisms of Resistance[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]PolyaminesPharmacology (medical)GeneComputingMilieux_MISCELLANEOUS030304 developmental biologyPharmacology0303 health sciences030306 microbiologyColistinNorspermidineHistidine kinaseGene Expression Regulation Bacterial[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyAnti-Bacterial AgentsResponse regulatorInfectious DiseasesAminoglycosideschemistryPseudomonas aeruginosaEffluxBacterial outer membraneTranscription Factors
researchProduct

Mechanisms of Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa : Results of the GERPA Multicenter Study

2020

ABSTRACT Resistance mechanisms of Pseudomonas aeruginosa to ceftolozane/tazobactam (C/T) were assessed on a collection of 420 nonredundant strains nonsusceptible to ceftazidime (MIC > 8 μg/ml) and/or imipenem (>4 μg/ml), collected by 36 French hospital laboratories over a one-month period (the GERPA study). Rates of C/T resistance (MIC > 4/4 μg/ml) were equal to 10% in this population (42/420 strains), and 23.2% (26/112) among the isolates resistant to both ceftazidime and imipenem. A first group of 21 strains (50%) was found to harbor various extended-spectrum β-lactamases (1 OXA-14; 2 OXA-19; 1 OXA-35; 1 GES-9; and 3 PER-1), carbapenemases (2 GES-5; 1 IMP-8; and 8 VIM-2), or both (1 VIM-2…

TazobactamImipenemPopulationCeftazidimeMicrobial Sensitivity TestsBiologymedicine.disease_causeCeftazidimeTazobactambeta-LactamasesMicrobiology03 medical and health sciencesCloxacillinMechanisms of Resistance[CHIM.ANAL]Chemical Sciences/Analytical chemistrymedicineHumans[CHIM]Chemical SciencesPseudomonas InfectionsPharmacology (medical)[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyeducationComputingMilieux_MISCELLANEOUS030304 developmental biologyPharmacology0303 health scienceseducation.field_of_study030306 microbiologyPseudomonas aeruginosabiochemical phenomena metabolism and nutritionAnti-Bacterial AgentsCephalosporins3. Good healthInfectious DiseasesPseudomonas aeruginosaColistinCeftolozanemedicine.drug
researchProduct